Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2024.65.305
Possible drug-drug interactions among elderly patients receiving antiviral therapy for chronic hepatitis B
Mehmet Çelik
; Department of Infectious Diseases and Clinical Microbiology, Harran University, Sanliurfa, Turkey
*
Yusuf Arslan
; Department of Infectious Diseases and Clinical Microbiology, Batman Training and Research Hospital, Batman, Turkey
Taylan Önder
; Department of Infectious Diseases and Clinical Microbiology, Osmaniye Kadirli State Hospital, Osmaniye, Turkey
Sevil Alkan
; Department of Infectious Diseases and Clinical Microbiology, Canakkale Onsekiz Mart University, Canakkale, Turkey
Ahmet Şahin
; Department of Infectious Diseases and Clinical Microbiology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey
Fethiye Akgül
; Department of Infectious Diseases and Clinical Microbiology, Batman Training and Research Hospital, Batman, Turkey
* Dopisni autor.
Sažetak
Aim To identify possible drug-drug interactions in patients
taking medications for other comorbidities while on antiviral therapy for chronic hepatitis B.
Methods The study enrolled patients with chronic hepatitis B aged ≥60 years who were treated with antiviral therapy in five hospitals in Turkey between January 1 and March
1, 2023. The Lexicomp® Drug Interactions program was
used to identify possible drug-drug interactions.
Results The study included 213 patients (119 [55.9%]
men). The mean age was 68.5 years. A potential drugdrug interaction was identified in 112 patients (52.6%). The
most common type of interaction was type C (“follow the
treatment”) (71.54%). The number of potential drug-drug
interactions increased with an increase in the number of
drugs used by the patients. A robust and affirmative correlation was observed between the number of medications
used and the number of possible drug-drug interactions
(r=0.791, P<0.001). Adverse interactions (interactions of
types C and D, 3.7% of cases) were limited to patients receiving tenofovir disoproxil fumarate.
Conclusion Nonsteroidal anti-inflammatory medications
should be used cautiously in elderly patients with chronic
hepatitis B treated with tenofovir disoproxil fumarate due
to the increased risk of renal toxicity
Ključne riječi
Hrčak ID:
336456
URI
Datum izdavanja:
20.8.2024.
Posjeta: 25 *